Dr Glen Reid was appointed ADRI’s Senior Research Scientist in April 2009, and he established the Institute’s cell and molecular biology labs. His research focuses on the identification of new markers and molecular targets for malignant mesothelioma. Previously he was Principal Investigator, Head of RNAi Product Development for Genesis Research & Development Corporation in New Zealand where he led a cancer RNAi discovery program. He was awarded a PhD from the University of Göttingen in Germany, after which completed his postdoctoral studies with Professor Piet Borst at The Netherlands Cancer Institute in Amsterdam, where his main focus was on the characterisation of multidrug resistance proteins.